Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

VitaNova Life Sciences (YJGJ) Equity Average (2018 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Equity Average for 8 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 84.67% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Oct 2025, up 84.67%, and an annual FY2025 reading of $1.5 million, up 197.44% over the prior year.
  • Equity Average was $1.9 million for Q4 2025 at VitaNova Life Sciences, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.9 million in Q3 2025 and bottomed at -$161888.5 in Q2 2021.
  • Average Equity Average over 5 years is $447475.0, with a median of -$23093.5 recorded in 2021.
  • The sharpest move saw Equity Average plummeted 236.58% in 2023, then skyrocketed 1789.44% in 2024.
  • Year by year, Equity Average stood at -$24602.5 in 2021, then decreased by 28.25% to -$31553.5 in 2022, then plummeted by 178.38% to -$87839.5 in 2023, then soared by 1259.13% to $1.0 million in 2024, then soared by 84.67% to $1.9 million in 2025.
  • Business Quant data shows Equity Average for YJGJ at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.5 million in Q2 2025.